{
    "clinical_study": {
        "@rank": "43775", 
        "brief_summary": {
            "textblock": "RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells.\n\n      PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy following surgery\n      in treating patients who have recurrent or second primary cancer of the head and neck\n      following previous radiation therapy."
        }, 
        "brief_title": "Radiation Therapy Following Surgery in Treating Patients With Recurrent or Second Primary Cancer of the Head and Neck Following Previous Radiation Therapy", 
        "condition": "Head and Neck Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Head and Neck Neoplasms", 
                "Neoplasms, Second Primary"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the survival and local control in previously irradiated patients at high risk\n           for local failure following regional resection of recurrent or second primary head and\n           neck cancer.\n\n        -  Determine the acute and late toxicities of this treatment in these patients.\n\n        -  Determine the pattern of disease failure in these patients on this treatment.\n\n        -  Determine any change in quality of life in these patients on this treatment.\n\n      OUTLINE: Patients receive fractionated doses of radiotherapy five times weekly for 6 weeks.\n\n      Quality of life is assessed prior to study, 2 months after radiotherapy, every 3 months for\n      remainder of year 1, every 4 months for years 2-3, every 6 months for years 4-5, and then\n      annually thereafter.\n\n      Patients are followed 2 months after radiotherapy, every 3 months for year 1, every 4 months\n      for year 2, every 6 months for years 3-5, and then annually thereafter.\n\n      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed squamous cell carcinoma of the mucosa, recurrent (primary\n             and/or nodal), or a second primary (positive or negative nodal), of one of the\n             following:\n\n               -  Oral cavity\n\n               -  Oropharynx\n\n               -  Hypopharynx\n\n               -  Larynx\n\n               -  Paranasal sinus\n\n               -  Neck disease of unknown origin\n\n          -  No distant metastases\n\n          -  No primary in the nasopharynx\n\n          -  Must have complete gross resection of disease\n\n          -  Must have positive final margins, soft tissue extension of primary, positive\n             extracapsular extension of lymph node disease, or at least 4 positive nodes without\n             extracapsular extension\n\n          -  Reirradiation field must overlap the previous field for a minimum of 3 cm in height,\n             width, and length\n\n               -  At least 6 months since prior radiotherapy with an overlap volume of at least 45\n                  Gy\n\n          -  No grade 3 or 4 toxicity for the following organ tissues:\n\n               -  RTOG grade 3 or 4 skin, subcutaneous tissue, larynx, joint, or RTOG grade 4\n                  mucous membrane or bone from prior radiotherapy\n\n          -  Radiotherapy must begin within 6-12 weeks of surgery\n\n          -  Prior radiotherapy records must be available\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  At least 3 months\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Not specified\n\n        Renal:\n\n          -  Not specified\n\n        Other:\n\n          -  Not pregnant\n\n          -  No history of invasive malignancy that would be expected to cause death within 3\n             years\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  Not specified\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n        Surgery:\n\n          -  See Disease Characteristics"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "January 28, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004226", 
            "org_study_id": "CDR0000067467", 
            "secondary_id": [
                "UAB-RAD-9601", 
                "UAB-F970430006", 
                "NCI-G99-1656"
            ]
        }, 
        "intervention": {
            "intervention_name": "radiation therapy", 
            "intervention_type": "Radiation"
        }, 
        "keyword": [
            "recurrent squamous cell carcinoma of the lip and oral cavity", 
            "recurrent squamous cell carcinoma of the hypopharynx", 
            "recurrent squamous cell carcinoma of the larynx", 
            "recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity", 
            "recurrent squamous cell carcinoma of the oropharynx", 
            "recurrent metastatic squamous neck cancer with occult primary"
        ], 
        "lastchanged_date": "December 3, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/UAB-RAD-9601"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294-3300"
                    }, 
                    "name": "University of Alabama at Birmingham Comprehensive Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Loma Linda", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92354"
                    }, 
                    "name": "Loma Linda University Cancer Institute at Loma Linda University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "Veterans Affairs Medical Center - Tampa (Haley)"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase I/II Study of High Dose Limited Volume Postoperative Reirradiation in Recurrent or Second Primary Carcinoma of the Head and Neck", 
        "overall_official": {
            "affiliation": "H. Lee Moffitt Cancer Center and Research Institute", 
            "last_name": "James L. Pearlman, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1/Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004226"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Alabama at Birmingham", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2004"
    }, 
    "geocoordinates": {
        "Loma Linda University Cancer Institute at Loma Linda University Medical Center": "34.048 -117.261", 
        "University of Alabama at Birmingham Comprehensive Cancer Center": "33.521 -86.802", 
        "Veterans Affairs Medical Center - Tampa (Haley)": "27.951 -82.457"
    }
}